

RESEARCH ARTICLE

Ultrasound-assisted magnetic nanoparticle-based gene delivery

Wei Zhang¹, Gaser N. Abdelrasoul¹, Oleksandra Savchenko², Abdalla Abdrabou³, Zhixiang Wang³, Jie Chen^{1,2*}

1 Department of Electrical and Computer Engineering, University of Alberta, Edmonton, Canada, **2** Department of Biomedical Engineering, University of Alberta, Edmonton, Canada, **3** Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada

* jc65@ualberta.ca

Abstract

Targeted gene delivery is important in biomedical research and applications. In this paper, we synergistically combine non-viral chemical materials, magnetic nanoparticles (MNPs), and a physical technique, low-intensity pulsed ultrasound (LIPUS), to achieve efficient and targeted gene delivery. The MNPs are iron oxide super-paramagnetic nanoparticles, coated with polyethyleneimine (PEI), which makes a high positive surface charge and is favorable for the binding of genetic materials. Due to the paramagnetic properties of the MNPs, the application of an external magnetic field increases transfection efficiency while LIPUS stimulation enhances cell viability and permeability. We found that stimulation at the intensity of 30 mW/cm² for 10 minutes yields optimal results with a minimal adverse effect on the cells. By combining the effect of the external magnetic field and LIPUS, the genetic material (GFP or Cherry Red plasmid) can enter the cells. The flow cytometry results showed that by using just a magnetic field to direct the genetic material, the transfection efficiency on HEK 293 cells that were treated by our MNPs was 56.1%. Coupled with LIPUS stimulation, it increased to 61.5% or 19% higher than the positive control (Lipofectamine 2000). Besides, compared with the positive control, our method showed less toxicity. Cell viability after transfection was 63.61%, which is 19% higher than the standard transfection technique. In conclusion, we designed a new gene-delivery method that is affordable, targeted, shows low-toxicity, yet high transfection efficiency, compared to other conventional approaches.

OPEN ACCESS

Citation: Zhang W, Abdelrasoul GN, Savchenko O, Abdrabou A, Wang Z, Chen J (2020) Ultrasound-assisted magnetic nanoparticle-based gene delivery. PLoS ONE 15(9): e0239633. <https://doi.org/10.1371/journal.pone.0239633>

Editor: Yogendra Kumar Mishra, University of Southern Denmark, DENMARK

Received: June 18, 2020

Accepted: September 9, 2020

Published: September 24, 2020

Copyright: © 2020 Zhang et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript and its Supporting Information files.

Funding: MITACS Canada Foundation for Innovation.

Competing interests: No authors have competing interests.

1. Introduction

Gene delivery is now a popular research area with high demand on the market, and applications in both clinical and scientific biomedical research [1, 2]. The applications include, but are not limited to, treating cancers, immune-deficient diseases, and genetic diseases [3]. Mammalian cells have a selectively permeable plasma membrane that protects them from the external environment. Effective methods to transfect cells are needed. For the delivery of genetic material into the nucleus of the cell, two approaches can be suggested: increasing the cell membrane permeability and thus facilitating the penetration of the target gene, or developing a

carrier that can go through the cell membrane, carry the gene and deliver it to the nucleus. Based on these two different pathways, gene delivery utilizes either chemical or physical methods [4, 5]. The chemical approaches can be further divided into viral and non-viral approaches [4]. The ideal carrier should be low cost, with high loading capacity, high stability, no or low toxicity, and easy to use [6]. The viral-vector system approach is the most common and widely used method [3], which can achieve very high transfection efficiency. However, the safety concerns related to immunogenicity and the high cost remain the main limitations [5]. Non-viral methods include liposome-based methods [7], calcium phosphate precipitation [8], cationic polymers [9, 10] (such as polyamidoamine dendrimers and PEI [11]), and nanoparticle-based hybrids [12]. The cationic liposomes are the most commonly used non-viral delivery system for gene delivery. They can reach most of the requirements of the ideal characteristics with the significant drawbacks of high toxicity and the inflammatory responses [7]. Calcium phosphate precipitation and PEI get low transfection efficiency and high cytotoxicity [8]. Nanoparticles are submicron-sized polymeric particles, due to the sub-cellular and sub-micron size range, they can penetrate tissues more efficiently [13]. MNP is one of the traditional nanoparticles and is also a popular carrier for gene delivery [14]. MNP can overcome the weaknesses of other traditional carriers, like high toxicity limiting the traditional carriers that can only be used *in vitro* [15]. The external magnetic fields applied on the target site not only can enhance the transfection, but also target the gene to a specific site without the side effects on other tissues. Due to this, MNPs can be tunable and focus on the target area, yet they still have some drawbacks like low transfection efficiency and toxicity [16].

Besides the chemical approach, the physical delivery methods are attracting more and more research interest, including the application of the electric field [17], the acoustic method [18], and physical injection [19], to disrupt the cell membrane and let the DNA pass through it more efficiently. Some physical techniques have shown sufficient delivery efficiency and can be applied to most of the cell types and are available for commercial use [20]. However, the main limitations are the cytotoxicity and the inability to be used in humans. Also, operational and equipment requirements are complicated and costly, and sometimes with low efficiency and repeatability. Acoustic methods are another physical approach to transfect the cells with the advantage of easy repeatability and excellent stability, yet with low transfection efficiency compared with other methods [18].

The ultrasound method is one of the acoustic transfection methods mentioned above, which is characterized by frequencies higher than 20 kHz. Ultrasound has been used for various applications, including diagnosis, surgery, and therapy for a long time [15, 21]. At its early implementations, researchers focused on the treatment produced by using the thermal effects of ultrasound. Nowadays, more researchers are paying attention to the non-thermal characteristic, including acoustic cavitation and mass transfer enhancement [22]. For ultrasound medical applications, the safe range of the intensity is between 0.05 W/cm² and 100 W/cm² [23, 24]. LIPUS is a particular type of ultrasounds shown in Fig 1, which generates at a frequency of 1–3 MHz and repeats at 1 kHz with a duty cycle of 20% to deliver a low-intensity pulsed-wave [25]. It has been proven to be very safe for human use for many aspects of the medical applications, such as bone healing [26], inflammation inhibiting [27], soft-tissue regeneration [28], and the induction of cell-membrane porosity. Using graphene aerogel to promote cell proliferation was reported [29, 30]. LIPUS has also been proven to help division and proliferation in many types of cells, such as insect cells [31], algal cells [32], stem/progenitor cell [33], mesenchymal stromal cells [34]. LIPUS can also increase CHO cell growth and antibody production [35], increase cell permeability [31], and enhance gene delivery by using microbubble [36]. The safe operational intensity range of LIPUS is between 0.02 and 1 W/cm² and treatment durations of 5–20 minutes per day. Because of its low intensity, LIPUS has almost no thermal effects [37].




Fig 1. A schematic for LIPUS device and ultrasound power meter calibration. The display shows the ultrasound intensity. The button can be employed to control the duty cycle and ultrasound stimulation duration. The ultrasound boxes include a motherboard, a control board, an ultrasound board, two driver boards, and a power board. We also include the circuit diagram.

<https://doi.org/10.1371/journal.pone.0239633.g001>

There are several ways to deliver genetic materials into cells. As mentioned in the introduction, we propose to synergistically combine LIPUS and magnetic fields for gene delivery, because the technique can leverage each method's advantages. LIPUS can promote cell growth [43] and enhance cell membrane permeability. At the same time, MNPs, guided by a magnetic field, can further improve targeted gene delivery. Best to our knowledge, combining the two techniques to deliver genetic material into mammalian cells has not been discussed before. We achieved a high transfection efficiency with low cytotoxicity by performing the cell transfection with LIPUS and MNPs under the external magnetic field. We present a new concept of integrating the physical and chemical gene delivery approaches by introducing LIPUS to support gene transfection using MNPs under the influence of the magnetic field. The plasmid of interest (GFP and Cherry Red plasmid) is firstly bound to the MNPs through PEI before introducing them to the cells. Then we investigate the impact of applying the magnetic field in combination with the LIPUS on the transfection of the targeted plasmid. We also examine the effect of the LIPUS on cell proliferation and viability to identify the proper ultrasound intensity and best duration of treatment that cells can tolerate. We used the fluorescent microscope for qualitative evaluation, whether this approach work or not, and then, employed flow cytometry to quantitatively evaluate the transfection efficiency and compare the results with those obtained from using Lipofectamine 2000 as a positive control. Furthermore, we also localized the transfected genes in the targeted cells using confocal microscopy. We have compared the transfection rates of various gene delivery methods. Please refer to the following Table 1. Our approach offers a combination of high efficiency with low toxicity and affordability.

Table 1. The transfection rate and cell viability of different delivery methods with HEK 293 cells.

Delivery Method	Transfection Rate	Cell Viability
PLGA-PEG/PBAE/pGFP Nanoparticle [38]	45.2%	97%
Magnetoplexes [39]	28.4%	97%
Lipoplexes [39]	45.5%	95%
Lipofectamine 2000	42.6%	44.7%
Thiolated trimethyl amino benzyl chitosan [40]	40.4%	90.0%
Magnetic Nanoparticles [16]	56.1%	58.3%
Our approach (MNPs & LIPUS)	61.5%	63.6%

<https://doi.org/10.1371/journal.pone.0239633.t001>

2. Materials and methods

2.1 Chemicals and materials

Anhydrous Ethylene glycol (EG) 99.8%, Ferric chloride hexahydrate ($\text{FeCl}_2 \cdot 6\text{H}_2\text{O}$) $\geq 99\%$, and anhydrous Sodium acetate $\geq 99\%$ (NaAc), and branched Polyethyleneimine PEI with average molecular weight (M.W.) 25 kDa were purchased from Sigma-Aldrich and used without further purification. HEK 293T cells (human embryonic kidney cells) were purchased from ATCC (ATCC CRL-11268), Minimum Essential Medium (MEM), Fetal Calf Serum (FCS), Penicillin/Streptomycin, PBS, Lipofectamine 2000, and DAPI were purchased from Thermofisher. Zombie Aqua was purchased from Biolegend. We used Milli-Q water with the resistivity of 18.2 M Ω from the Millipore Milli-Q Advantage A10 purification system in all experiments.

Magnet: The magnet, made of neodymium (rare earth) with a diameter of 10 cm and a thickness of 10 cm, was purchased from Applied Magnets (Plano, TX, USA).

2.2. Cell culture

HEK 293T cells were cultured in high glucose MEM medium, supplemented with 10% FCS and 1% penicillin/streptomycin at 37°C and 5% CO₂. Cells were passed to a 12-well plate before the experiment, and transfection was performed in the 12-well plate once the cells reached 60–80% confluency, which is recommended for the transfection.

2.3. Synthesis and functionalization of MNPs

MNPs were synthesized using the hydrothermal method, according to our previously reported work [15, 16]. In short, a reaction mixture containing 10 g 1,6-hexanediamide, 2.0 g $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$, and 4.0 g sodium acetate trihydrate ($\text{NaAc} \cdot 3\text{H}_2\text{O}$) in 50 mL of ethylene glycol (EG) was vigorously stirred at 85°C for 2 h until a resulting transparent solution was obtained. To complete the reaction, the solution was sealed in a 100 mL Teflon-lined stainless-steel autoclave and put the oven for 12 h at 200°C. After completion, the MNPs solution was cooled down to room temperature and collected with the help of a magnet and further redispersed in milli-Q water by sonication for 15 min. MNPs were washed with water three times, where the MNPs were redispersed by sonication and collected each time with the help of the magnet. Then we also washed with absolute ethanol following the same method to ensure the complete removal of unreacted materials with the abbreviation of FN. Finally, the prepared MNPs (or FN-MNPs) were dispersed in 100 mL milli-Q water for characterization and further use.

For functionalization, FN-MNPs were treated with a 5% glutaraldehyde solution for 2 hours, then washed three times with Milli-Q water and further coated with 1 mg/mL solution of PEI (25 KDa) to produce FN-Glu and FN-Glu-PEI25K, respectively. PEI is known to assist




Fig 2. Characterization and functionalization of MNPs (a) MNPs size distribution under TEM. (b) Hydrodynamic size and ζ potential for particles. Here, FN stands for MNPs, FN-Glu stands for MNPs after glutaraldehyde treatment, and FN-Glu-PEI25K stands for MNPs after glutaraldehyde treatment coated with PEI.

<https://doi.org/10.1371/journal.pone.0239633.g002>

in cell transfection, yet it is toxic to the cells. We selected PEI as a cationic surfactant to coat the magnetic nanoparticles (MNPs) because of its high affinity to bind with negatively charged plasmid. The PEI molecules are covalently bound to the MNPs, which significantly decreases the potential toxicity associated with using cationic surfactants. Furthermore, the complex of the negatively charged plasmid with FN-Glu-PEI25K MNPs mitigates the positive charge of the FN-Glu-PEI25K MNPs. We previously utilized FN-Glu-PEI25K MNPs as gene nano-carriers, and the GFP plasmid/ FN-Glu-PEI25K MNPs showed lower toxicity than the positive control (lipofectamine 2000) [16, 41].

The size of nanoparticles was estimated using Hitachi HF-3300 Transmission Electronic Microscope (300 kVTEM), where we measured the size of 150 nanoparticles using ImageJ software, and the size of the nanoparticles was calculated based on the histogram of the size distribution. The prepared MNPs were ~ 24 nm in size, as shown in Fig 2a.

The ζ potential and the hydrodynamic size of the MNPs were measured using Zetasizer Nano ZS Malvern Panalytical. The hydrodynamic size and zeta potential for our nanoparticles were evaluated and shown in Fig 2b. Unlike the FN and FN-Glu, we got a high positive surface charge of Zeta potential for FN-Glu-PEI25K. They all have different hydrodynamic sizes, but FN-Glu-PEI25K showed a higher density of PEI on the MNPs surface for DNA binding.

2.4 Ultrasound stimulation device

Cells were exposed to ultrasound stimulation using the LIPUS device developed previously in our lab. The LIPUS device outputs a square wave with a frequency of 1.5 MHz. The repetition

rate is 1 kHz, and the duty cycle is 20%. We can adjust the output voltage from 1.25V to 12.5V by adjusting the potentiometer. Along with the increase of the ultrasound intensity, the output voltage increases too. The PCB board is shown in Fig 1 and has 6 boards in the box, including a motherboard, a control board, a power board, an ultrasound board, and two driver boards. The motherboard is used to connect all other boards. The control board is used to control the ultrasound intensity and duration. The ultrasound board is used to supply an ultrasound signal with a frequency of 1.5 MHz and a repetition rate of 1 kHz, and the driver board is used to provide enough voltage and current to drive the transducers. Ultrasound settings can be controlled and adjusted.

Ultrasound transducers: Two ultrasound transducers we used in the LIPUS device were purchased from American Piezo Company (APC) International, Ltd (Mackey Ville, USA). The piezo-crystal 880 inside the transducer has a diameter of 25 mm and a thickness of 12.5 mm. Although the diameter of each well in a 12-well cell culture plate is 22 mm, the diameter of the transducer is slightly bigger than the well. However, it does not affect the results because we purposely calibrate the transducer with an intensity of $30\text{mW}/\text{cm}^2$, not the overall power. It has a resonant frequency of 1.5 MHz and a piezoelectric charge constant d_{33} of 215 m/V. The ultrasound power meter we used to measure the ultrasound intensity was purchased from Ohmic Instruments Co., Maryland, USA, and the model is UPM-DT-1AV. The diameter of the transducer is 25 mm, and thus its active area is 4.9 cm^2 . For instance, if we want to have the output intensity of $30\text{ mW}/\text{cm}^2$, the measured output power should be $4.9 \times 30 = 147\text{ mW} = 0.147\text{ W}$. The minimum measurement changing value of this power meter is 0.002 W . Therefore, in a real operation, we adjust the resistance of the potentiometer to get the readings as 0.146 W , or 0.148 W . Each of the transducers was calibrated before the experiment using a degassed water tank, in which transducer was fixed using a holder until the reading of the output was stable.

2.5 Cells transfection

Transfection was performed at 60–80% cell confluency. GFP plasmid or Red Cherry plasmid were used as genetic material to transfect. $1\mu\text{g}$ purified plasmid was mixed with $3\mu\text{L}$ MNPs both previously diluted in $500\mu\text{L}$ serum-free medium to a total volume of $1000\mu\text{L}$ and then thoroughly mixed and left for 30 min. The serum can interfere with the formation of the complex of DNA with MNPs [42]. After 30 minutes, the medium was removed from the cell wells and replaced with the mixture of MNPs-DNA complexes. To direct the MNPs into the cells, we then put the plate on the LIPUS/magnet device and treated cells for 10 minutes. After that, we stopped the LIPUS and incubated the cells on the magnet for 4 more hours. The medium was then replaced with 10% serum MEM medium, and cells were further grown in the incubator for up to 48 hours.

For the Lipofectamine 2000 transfection, $1\mu\text{g}$ purified plasmid was mixed with $3\mu\text{L}$ lipofectamine in serum-free MEM and left for 30 mins. We added the DNA-lipofectamine complex to the cells after the 30-minute incubation.

2.6 Experimental setup

After mixing cells with the genetic material of interest and transfection reagent (MNPs or Lipofectamine), the cell plate was placed on the ultrasound transducer with the ultrasound gel connection for 10 min treatment. After that, the plate was put on top of a strong magnet below the transducer. After the treatment, the ultrasound device was removed, and the cells were kept on the magnet for 4 hours. Transfection efficiency was checked within 24–48 hours after the experiment.

2.7 Transfection evaluation/characterization

Cell transfection efficiency was evaluated within 48 hours after the experiment using several methods. Confocal microscopy images were obtained using the Zeiss LSM 710 confocal microscope. For the confocal microscope imaging, cells were cultured and transfected on the coverslip using the same protocol mentioned above, and after 48 hours were fixed in the 4% PFA and stained with DAPI. Fluorescent microscope images were obtained by Zeiss, Axiovert 200 fluorescent microscope. For the qualitative evaluation of transfection during the method development, fluorescent microscopy was used. Cells after transfection were checked within 24–48 hours for the fluorescent protein expression. As a negative control, untreated HEK 293T cells were used. Both groups of cells were fixed in 4% freshly prepared paraformaldehyde (PFA) for 10 minutes.

2.8. Flow cytometry

The quantification of the transfection efficiency was performed using Attune X Flow Cytometer. Flow cytometry was performed with Zombie Aqua as our cell viability dye in dilution of 1:250, which was selected based on the pre-experimental titration and gave the clearest separation of the dead and alive cells. In the Flow Cytometry experiment, aside from experimental groups of samples, we used compensation controls, positive control, and negative control to assure the accuracy of the results.

1. For the negative control, untreated cells without any genetic material and viability dye were used.
2. As there were two main fluorophores, we used two compensation controls to prevent the spills: For Zombie Aqua compensation, we used cells, stained with viability dye; For GFP or Cherry Red compensation, we used cells transfected with a plasmid (GFP or Cherry respectively) and Lipofectamine as transfection agent.
3. For the positive control, the purified plasmid was used for transfection, and Lipofectamine as a golden standard for transfection available on the market, and cells were stained with Zombie Aqua after 48 hours.
4. For the experimental group, two groups were set to evaluate the effect of LIPUS on the MNPs transfection and cell viability. First group: cells, plasmid, and MNPs were treated with magnet for 4 hours and stained with viability dye after 48 hours. The other group was additionally treated with LIPUS device (10 mins duration at $30\text{mW}/\text{cm}^2$ intensity) and a magnet for 4 hours and then stained after 48 hours.

2.9 Statistical analysis

Each experiment was repeated at least three times. The data was presented by including means and standard deviation. The statistical analyses between different groups were conducted by one-way ANOVA paired t-test. $p < 0.05$ were considered as statically significant.

3. Results and discussions

In this paper, we combined both physical and chemical approaches to develop a high-efficient gene delivery method with low-cytotoxicity. From the previous work done in our group as well as by other groups and reported in the literature, we knew that LIPUS could transiently increase cell membrane permeability [31] as well as can be beneficial for cell viability [35, 43].

Our goal was to evaluate whether ultrasound can enhance the entry of genes into the cells when used with MNPs as a transfection tool.

3.1 Selecting optimal ultrasound condition

Different ultrasound parameters, such as wave intensity, treatment duration, and frequency of the treatment, can have a significantly different effect on the cell growth and membrane permeability [31, 35]. Therefore, we needed to select the optimal conditions of the LIPUS stimulation for our studies. In our experiments, five different ultrasound intensities and durations were selected. These conditions were (1) the control (no LIPUS stimulation); (2) LIPUS at 30 mW/cm² for 5 minutes; (3) LIPUS at 40 mW/cm² for 5 minutes; (4) 30 mW/cm² for 10 minutes; and (5) 40 mW/cm² for 10 minutes. These conditions were selected based on our previous successful studies; for instance, 30 mW/cm² showed the optimal performance for stimulating mammalian cells [43]. For the successful penetration of ultrasound waves to stimulate the targeted cells, ultrasound gel has to be applied on the surface of the ultrasound transducer, because ultrasound does not propagate through the air. If we do not use the ultrasound gel, the transmission coefficient of sound intensity can be 0.00923%. When we use the ultrasound gel, the transmission coefficient of sound intensity can be 31.1%, and thus the ultrasound gel is necessary.

To select the optimal duration of LIPUS treatment, several stimulation conditions were evaluated, and cell counting was also performed. The results are shown in Fig 3, where the cells treated for 10 minutes under 30mW/cm² showed the best result with a p-value of 0.00128. P-values for the other stimulation conditions are greater than 0.05 (5 minutes and 30 mW/cm²: p = 0.5, 10 minutes and 40 mW/cm²: p = 0.204), which means there is no statistical difference. Consequently, we use the LIPUS device for 10 minutes under the intensity of 30 mW/cm² in our transfection experiments. In our tests, we used two ultrasound transducers at the same time to treat the cells in 2 wells (our experiment design and setup can allow up to six wells to be treated at the same time).




Fig 3. Cell proliferation after stimulation with LIPUS under different intensity and duration parameters. (*: p < 0.05, **: < 0.01).

<https://doi.org/10.1371/journal.pone.0239633.g003>




Fig 4. Fluorescence microscope images: (a) negative control (just cells), (b) (c) cells transfected with GFP with MNPs and treated with LIPUS. Scale bars = 100 μ m.

<https://doi.org/10.1371/journal.pone.0239633.g004>

3.2 Fluorescent microscope results

Fluorescent microscopy allowed for an easy way to qualitatively evaluate the efficacy of the combined gene delivery method in the process of method development. The negative control, which just contained the GFP plasmid in the cell plates, showed no transfected cells (Fig 4a), confirming that the plasmid itself does not cross the cell membrane without a delivery carrier. Compared to the negative control, using MNPs along with LIPUS treatment introduced the green fluorescent spots in the images (Fig 4b and 4c), showing the cells that have been successfully transfected with the GFP plasmid and GFP expressed. These fluorescent images were good indicators that our method could work well and were very useful for method development as those allowed for fast qualitative screening of each experiment.

3.3 Transfection efficiency using flow cytometry

At the same time, the fluorescent microscope images could only give us the qualitative evaluation of whether our new physical and chemical combined approach worked for gene delivery. Once we had our method working, we had to quantify its efficiency and, whether it could be offered as an alternative to the available transfection tools on the market. We were focused on the parameters of transfection efficiency, cell viability, and how they can be compared with the results of the standard gene delivery approach using Lipofectamine 2000, a well-known and efficient transfection reagent, shown in Fig 5b. The average transfection efficiency of the Lipofectamine 2000 in our experiments was 42.62%, as shown in Fig 5a, and it was within the range of normal performance of Lipofectamine 2000 working on HEK 293T cells. This result ensured that our HEK cells were always in good condition before we performed the transfection steps, and we got the proper operations during the transfection.

Compared to the standard Lipofectamine 2000 reagent mentioned above, the MNPs alone and MNPs coupled with LIPUS stimulation gave us better results (shown in Fig 5a). They increased the transfection efficiency 1.3- and 1.45- fold, respectively, over the Lipofectamine 2000. Fig 5c is the histogram plot of flow cytometry, showing the GFP fluorescence of the experimental group transfected with GFP plasmid, MNPs, and external magnetic field. The transfection efficiency was 57.503%, 13% higher than the Lipofectamine 2000, which indicated that the MNPs themselves could perform better than the Lipofectamine under the external magnetic field. Fig 5d is the histogram plot of cytometry by combining the MNPs and the LIPUS stimulation with the transfection rate of 61.52%. By synergistically combining MNPs and LIPUS, we can achieve efficient and targeted gene delivery. We also ran an experiment with MNPs, but without the application of the external magnetic field and the transfection




Fig 5. Quantification of transfection: (a) Overall transfection efficiency and cell viability results. (**: $p < 0.01$, ***: $p < 0.001$). Subfigures (b)-(i) show the flow cytometry histogram plots of transfection rates using GFP with different methods. (b) lipofectamine 2000, (c) our MNPs and magnet, $p < 0.001$ (d) our suggested method: MNPs, magnet, in combination with LIPUS treatment, $p < 0.001$. (e) MNPs only, (f) treated only with LIPUS. Cell viability results in the presence of Zombie Aqua viability dye when transfected with (g) lipofectamine 2000. (h) MNPs and magnet, $p < 0.01$, (i) MNPs, magnet, and LIPUS, $p < 0.001$.

<https://doi.org/10.1371/journal.pone.0239633.g005>

efficiency was only 14%, as shown in Fig 5e. This is consistent with the idea that MNPs, as a gene carrier, cannot efficiently deliver the material without the external magnet field targeting.

For the development of additional LIPUS stimulation step of our method, we first selected the ultrasound condition using 10 minutes of treatment with an intensity of 30 mW/cm^2 . We

then performed the transfection using our experimental setup with the LIPUS device. We got the average transfection result of 61.52%, showing the highest transfection efficiency among our samples with the p-value of 0.0001. As a control, cells mixed with the genetic material (plasmid of interests) and treated with ultrasound were used to evaluate the effect of just LIPUS stimulation on the transfection without the MNPs/magnetic field. In that experiment, the transfection rate was only at 1%, as shown in Fig 5f, indicating that LIPUS alone could not transfect the cells without the carriers. Our results showed that, though LIPUS waves could not function as a tool for transfection itself, it could permeabilize cell membranes and, coupled with another tool (i.e., MNPs in this case), could enhance gene delivery into the cells.

3.4 Cell toxicity results

In our experiment, we used viability assay (Zombie Aqua) to evaluate the viability of HEK cells in our tests with different gene delivery approaches. Fig 5g, 5h and 5i shows three different groups of cell viability results (Group 1: Lipofectamine 2000, Group 2: MNPs/magnetic field without LIPUS stimulation, Group 3: MNPs/magnetic field plus LIPUS), and the overall results are showing in Fig 5a. The negative control group (just untreated cells) showed viability at 91.524%, which was used as the background for all the results. Lipofectamine 2000 gave us 44.68% cell viability. MNPs showed 14% higher cell viability than the Lipofectamine 2000, indicating that our MNPs had lower cytotoxicity. The addition of the LIPUS device stimulation to the MNPs delivery further increased cell viability by up to 63.61% after the transfection with the p-value of 0.0002. These results showed that the LIPUS wave could stimulate cell growth and enhance cell viability.

3.5 Confocal microscope results

For confocal microscopy, the cells were transfected using the same protocol, but they were cultured on slides instead of a 12-well plate. Cells were stained with DAPI to evaluate the location of the gene in the transfected cells. Fig 6 shows the confocal microscopy results of the cells after transfection within 48 hours. In the figure, with both Cherry Red plasmid and GFP plasmid HEK cells were sufficiently transfected using our developed technique. The merged images indicate gene mostly accumulated and expressed in the nucleus, where the Dapi stains, confirming the successful delivery of the genetic material to the nucleus.

4. Conclusions

In this study, we combined the application of an external magnetic field with MNPs and LIPUS stimulation for gene delivery. The uniqueness of our design is that, in addition to MNPs, used as a transfection carrier, we used the LIPUS cell stimulation to enhance gene delivery through increased cell permeability. In our experiments, we did the transfection on the HEK cells using our nanoparticles and got a 14% higher transfection rate, compared to the Lipofectamine 2000. The transfection efficiency further increases by 5%, when we add the LIPUS cell stimulation to the whole system, which was in line with our expectations. As for the cell viability, Lipofectamine is known for its cytotoxicity and showed only 44.48% cell viability in our transfection experiments. The higher percentage of cells were alive after transfection when we used the MNPs with viability up to 58.31%. LIPUS stimulation added as an extra step during the MNPs transfection yielded even higher cell viability at 63.61%, compared to the MNPs only.

It is worth mentioning that our results and the Lipofectamine 2000 results were compared in terms of both the transfection efficiency and cell viability, and our technique showed better performance. LIPUS was shown to promote cell permeability and let the MNPs-DNA complex




Fig 6. Fluorescent images of cells transfected different plasmids using both MNPs and LIPUS stained with DAPI, (a) Cherry-red, (b) GFP. (c) The control group (just cells). Scale bars = 20 μm .

<https://doi.org/10.1371/journal.pone.0239633.g006>

pass through and thus to increase the transfection efficiency and enhance the cell viability. Because our assay is 10x cheaper than Lipofectamine 2000 and is also a chemical-based physical delivery approach, it can be an attractive gene-delivery method for other hard-to-transfect cells (such as primary cells and neuron cells) and *in vivo*.

Supporting information

S1 Fig. (a) LIPUS generation box, (b) photograph of the setup for measuring acoustic impedance.

(DOCX)

S2 Fig. An example of quantification of transfection: (a)-(c) show the flow cytometry histogram plots of transfection rates and cell viability using GFP with different methods. (a) lipofectamine 2000, (b) our MNPs and magnet, (c) our suggested method: MNPs, magnet, in

combination with LIPUS treatment.
(DOCX)

S3 Fig. Another example of quantification of transfection: (a)-(c) show the flow cytometry histogram plots of transfection rates and cell viability using GFP with different methods.

(a) lipofectamine 2000, (b) our MNPs and magnet, (c) our suggested method: MNPs, magnet, in combination with LIPUS treatment.
(DOCX)

S4 Fig. Cell proliferation after stimulation with LIPUS under 10 different intensity and duration parameters.

(DOCX)

S1 Table. Cell proliferation after stimulation with LIPUS under 10 different intensity and duration parameters.

(DOCX)

S2 Table. Cell proliferation after stimulation with LIPUS under 4 different intensity and duration parameters.

(DOCX)

S1 Graphical abstract.

(TIF)

Acknowledgments

We would like to thank Geraldine Barron from the Cross-Cancer Institute in Edmonton, Canada, for helping us with the confocal microscope and Hamid Maadi for assisting us with the fluorescent microscope. The flow cytometry experiments were performed at the Flow Cytometry Facility, Faculty of Medicine & Dentistry, University of Alberta. The facility receives financial support from the Faculty of Medicine & Dentistry and the Canada Foundation for Innovation (CFI).

Author Contributions

Conceptualization: Jie Chen.

Data curation: Wei Zhang, Gaser N. Abdelrasoul, Oleksandra Savchenko, Abdalla Abdrabou.

Formal analysis: Wei Zhang.

Funding acquisition: Jie Chen.

Investigation: Jie Chen.

Methodology: Gaser N. Abdelrasoul, Oleksandra Savchenko, Abdalla Abdrabou, Zhixiang Wang, Jie Chen.

Project administration: Zhixiang Wang, Jie Chen.

Resources: Jie Chen.

Supervision: Zhixiang Wang, Jie Chen.

Writing – original draft: Wei Zhang, Gaser N. Abdelrasoul, Oleksandra Savchenko, Jie Chen.

Writing – review & editing: Wei Zhang, Gaser N. Abdelrasoul, Oleksandra Savchenko, Jie Chen.

References

1. Evans C. H., Gene therapy for bone healing. *Expert reviews in molecular medicine* 2010, 12. <https://doi.org/10.1017/S1462399410001493> PMID: 20569532
2. Davidson J. M., First-class delivery: getting growth factors to their destination. *Journal of Investigative Dermatology* 2008, 128 (6), 1360–1362. <https://doi.org/10.1038/jid.2008.128> PMID: 18478013
3. Naldini L., Gene therapy returns to centre stage. *Nature* 2015, 526 (7573), 351–360. <https://doi.org/10.1038/nature15818> PMID: 26469046
4. Wang W.; Li W.; Ma N.; Steinhoff G., Non-viral gene delivery methods. *Current pharmaceutical biotechnology* 2013, 14 (1), 46–60. PMID: 23437936
5. Elsabahy M.; Nazarali A.; Foldvari M., Non-viral nucleic acid delivery: key challenges and future directions. *Current drug delivery* 2011, 8 (3), 235–244. <https://doi.org/10.2174/156720111795256174> PMID: 21291381
6. Semple S. C.; Harasym T. O.; Clow K. A.; Ansell S. M.; Klimuk S. K.; Hope M. J., Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid. *Journal of Pharmacology and Experimental Therapeutics* 2005, 312 (3), 1020–1026. <https://doi.org/10.1124/jpet.104.078113> PMID: 15525796
7. Luo D.; Saltzman W. M., Synthetic DNA delivery systems. *Nature biotechnology* 2000, 18 (1), 33–37. <https://doi.org/10.1038/71889> PMID: 10625387
8. Roy I.; Mitra S.; Maitra A.; Mozumdar S., Calcium phosphate nanoparticles as novel non-viral vectors for targeted gene delivery. *International Journal of Pharmaceutics* 2003, 250 (1), 25–33. [https://doi.org/10.1016/s0378-5173\(02\)00452-0](https://doi.org/10.1016/s0378-5173(02)00452-0) PMID: 12480270
9. Davis M. E., Non-viral gene delivery systems. *Current opinion in biotechnology* 2002, 13 (2), 128–131. [https://doi.org/10.1016/s0958-1669\(02\)00294-x](https://doi.org/10.1016/s0958-1669(02)00294-x) PMID: 11950563
10. Belguise-Valladier P.; Behr J.-P., Nonviral gene delivery: towards artificial viruses. *Cytotechnology* 2001, 35 (3), 197–201. <https://doi.org/10.1023/A:1013133605406> PMID: 22358859
11. Khosravi D. K.; Mozafari M. R.; Rashidi L.; Mohammadi M., Calcium based non-viral gene delivery: an overview of methodology and applications. 2010. PMID: 21137647
12. Ravi Kumar M.; Hellermann G.; Lockey R. F.; Mohapatra S. S., Nanoparticle-mediated gene delivery: state of the art. *Expert opinion on biological therapy* 2004, 4 (8), 1213–1224. <https://doi.org/10.1517/14712598.4.8.1213> PMID: 15268657
13. Zuris J. A.; Thompson D. B.; Shu Y.; Guilinger J. P.; Bessen J. L.; Hu J. H., et al., Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. *Nature biotechnology* 2015, 33 (1), 73. <https://doi.org/10.1038/nbt.3081> PMID: 25357182
14. Dobson J., Gene therapy progress and prospects: magnetic nanoparticle-based gene delivery. *Gene therapy* 2006, 13 (4), 283–287. <https://doi.org/10.1038/sj.gt.3302720> PMID: 16462855
15. Vinogradov S. V.; Bronich T. K.; Kabanov A. V., Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. *Advanced drug delivery reviews* 2002, 54 (1), 135–147. [https://doi.org/10.1016/s0169-409x\(01\)00245-9](https://doi.org/10.1016/s0169-409x(01)00245-9) PMID: 11755709
16. Nguyen A. H.; Abdelrasoul G. N.; Lin D.; Maadi H.; Tong J.; Chen G.; et al., Polyethylenimine-coated iron oxide magnetic nanoparticles for high efficient gene delivery. *Applied Nanoscience* 2018, 8 (4), 811–821.
17. Neumann E.; Schaefer-Ridder M.; Wang Y.; Hofschneider P., Gene transfer into mouse lyoma cells by electroporation in high electric fields. *The EMBO journal* 1982, 1 (7), 841–845. PMID: 6329708
18. Liu Y.; Yan J.; Prausnitz M. R., Can ultrasound enable efficient intracellular uptake of molecules? A retrospective literature review and analysis. *Ultrasound in medicine & biology* 2012, 38 (5), 876–888. <https://doi.org/10.1016/j.ultrasmedbio.2012.01.006> PMID: 22425381
19. Wolff J. A.; Malone R. W.; Williams P.; Chong W.; Acsadi G.; Jani A.; et al., Direct gene transfer into mouse muscle in vivo. *Science* 1990, 247 (4949), 1465–1468. <https://doi.org/10.1126/science.1690918> PMID: 1690918
20. Stewart M. P.; Sharei A.; Ding X.; Sahay G.; Langer R.; Jensen K. F., In vitro and ex vivo strategies for intracellular delivery. *Nature* 2016, 538 (7624), 183–192. <https://doi.org/10.1038/nature19764> PMID: 27734871
21. Ensminger D.; Bond L. J., *Ultrasonics: fundamentals, technologies, and applications*. CRC press: 2011.
22. Lin G.; Reed-Maldonado A. B.; Lin M.; Xin Z.; Lue T. F., Effects and mechanisms of low-intensity pulsed ultrasound for chronic prostatitis and chronic pelvic pain syndrome. *International journal of molecular sciences* 2016, 17 (7), 1057. <https://doi.org/10.3390/ijms17071057> PMID: 27376284

23. Pounder N. M.; Harrison A. J., Low intensity pulsed ultrasound for fracture healing: a review of the clinical evidence and the associated biological mechanism of action. *Ultrasonics* 2008, 48 (4), 330–338. <https://doi.org/10.1016/j.ultras.2008.02.005> PMID: 18486959
24. Ter Haar G., Therapeutic ultrasound. *European Journal of Ultrasound* 1999, 9 (1), 3–9. [https://doi.org/10.1016/s0929-8266\(99\)00013-0](https://doi.org/10.1016/s0929-8266(99)00013-0) PMID: 10099161
25. Jiang X.; Savchenko O.; Li Y.; Qi S.; Yang T.; Zhang W.; et al., A review of low-intensity pulsed ultrasound for therapeutic applications. *IEEE Transactions on Biomedical Engineering* 2018, 66 (10), 2704–2718. <https://doi.org/10.1109/TBME.2018.2889669> PMID: 30596564
26. Malizos K. N.; Hantes M. E.; Protopappas V.; Papachristos A., Low-intensity pulsed ultrasound for bone healing: an overview. *Injury* 2006, 37 (1), S56–S62. <https://doi.org/10.1016/j.injury.2006.02.037> PMID: 16581076
27. Xin Z.; Lin G.; Lei H.; Lue T. F.; Guo Y., Clinical applications of low-intensity pulsed ultrasound and its potential role in urology. *Translational andrology and urology* 2016, 5 (2), 255. <https://doi.org/10.21037/tau.2016.02.04> PMID: 27141455
28. Khanna A.; Nelmes R. T.; Gougoulias N.; Maffulli N.; Gray J., The effects of LIPUS on soft-tissue healing: a review of literature. *British medical bulletin* 2009, 89 (1), 169–182. <https://doi.org/10.1093/bmb/ldn040> PMID: 19011263
29. Bajpai V. K.; Shukla S.; Khan I.; Kang S.-M.; Haldorai Y.; Tripathi K. M.; et al., A Sustainable Graphene Aerogel Capable of the Adsorptive Elimination of Biogenic Amines and Bacteria from Soy Sauce and Highly Efficient Cell Proliferation. *ACS applied materials & interfaces* 2019, 11 (47), 43949–43963. <https://doi.org/10.1021/acsami.9b16989> PMID: 31684721
30. Shukla S.; Khan I.; Bajpai V. K.; Lee H.; Kim T.; Upadhyay A.; et al., Sustainable graphene aerogel as an ecofriendly cell growth promoter and highly efficient adsorbent for histamine from red wine. *ACS applied materials & interfaces* 2019, 11 (20), 18165–18177. <https://doi.org/10.1021/acsami.9b02857> PMID: 31025849
31. Xing J.; Singh S.; Zhao Y.; Duan Y.; Guo H.; Hu C.; et al., Increasing vaccine production using pulsed ultrasound waves. *PloS one* 2017, 12 (11). <https://doi.org/10.1371/journal.pone.0187048> PMID: 29176801
32. Savchenko O.; Xing J.; Yang X.; Gu Q.; Shaheen M.; Huang M.; et al., Algal cell response to pulsed waved stimulation and its application to increase algal lipid production. *Scientific reports* 2017, 7, 42003. <https://doi.org/10.1038/srep42003> PMID: 28186124
33. Xu P.; Gul-Uludag H.; Ang W. T.; Yang X.; Huang M.; Marquez-Curtis L.; et al., Low-intensity pulsed ultrasound-mediated stimulation of hematopoietic stem/progenitor cell viability, proliferation and differentiation in vitro. *Biotechnology letters* 2012, 34 (10), 1965–1973. <https://doi.org/10.1007/s10529-012-0984-6> PMID: 22763849
34. Huang D.; Gao Y.; Wang S.; Zhang W.; Cao H.; Zheng L.; et al, Impact of low-intensity pulsed ultrasound on transcription and metabolite compositions in proliferation and functionalization of human adipose-derived mesenchymal stromal cells. *Scientific Reports* 2020. <https://doi.org/10.1038/s41598-020-69430-z> PMID: 32792566
35. Zhao Y.; Xing J.; Xing J. Z.; Ang W. T.; Chen J., Applications of low-intensity pulsed ultrasound to increase monoclonal antibody production in CHO cells using shake flasks or wavebags. *Ultrasonics* 2014, 54 (6), 1439–1447. <https://doi.org/10.1016/j.ultras.2014.04.025> PMID: 24841953
36. He C.; Gu Q.; Zeng H.; Zhang H.; Huang M.; Yang X.; et al., Microbubble-enhanced cell membrane permeability in high gravity field. *Cellular and Molecular Bioengineering* 2013, 6 (3), 266–278.
37. Baker K. G.; Robertson V. J.; Duck F. A., A review of therapeutic ultrasound: biophysical effects. *Physical therapy* 2001, 81 (7), 1351–1358. PMID: 11444998
38. Li Z.; Ho W.; Bai X.; Li F.; Chen Y.-j.; Zhang X.-Q.; et al., Nanoparticle depots for controlled and sustained gene delivery. *Journal of Controlled Release* 2020. <https://doi.org/10.1016/j.jconrel.2020.03.021> PMID: 32194173
39. Villate-Beitia I.; Puras G.; Soto-Sánchez C.; Agirre M.; Ojeda E.; Zarate J.; et al., Non-viral vectors based on magnetoplexes, lipoplexes and polyplexes for VEGF gene delivery into central nervous system cells. *International journal of pharmaceutics* 2017, 521 (1–2), 130–140. <https://doi.org/10.1016/j.ijpharm.2017.02.016> PMID: 28185961
40. Rahmani S.; Hakimi S.; Esmaeily A.; Samadi F. Y.; Mortazavian E.; Nazari M.; et al., Novel chitosan based nanoparticles as gene delivery systems to cancerous and noncancerous cells. *International journal of pharmaceutics* 2019, 560, 306–314. <https://doi.org/10.1016/j.ijpharm.2019.02.016> PMID: 30797073
41. Jin W.; Lin D.; Nguyen A. H.; Abdelrasoul G. N.; Chen J.; Mar A.; et al., Transfection of difficult-to-transfect rat primary cortical neurons with magnetic nanoparticles. *Journal of biomedical nanotechnology* 2018, 14 (9), 1654–1664. <https://doi.org/10.1166/jbn.2018.2604> PMID: 29958559

42. Yang J.; Huang L., Overcoming the inhibitory effect of serum on lipofection by increasing the charge ratio of cationic liposome to DNA. *Gene therapy* 1997, 4 (9), 950–960. <https://doi.org/10.1038/sj.gt.3300485> PMID: [9349432](https://pubmed.ncbi.nlm.nih.gov/9349432/)
43. Chen, J.; James, X.; Ang, W. T.; Gul, H., Enhanced animal cell growth using ultrasound. Google Patents: 2015.